Log in

Relevant bibliographies by topics / Activated partial thromboplastin time / Journal articles

To see the other types of publications on this topic, follow the link: Activated partial thromboplastin time.

Journal articles on the topic 'Activated partial thromboplastin time'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Activated partial thromboplastin time.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ciavarella, N., S. Coccheri, P. M. Mannucci, M. Teresa Canciani, G. Mariani, P. G. Mori, Maria Orlando, L. Tentori, and O. Ponari. "Activated Partial Thromboplastin Time." Scandinavian Journal of Haematology 25, no. 4 (April 24, 2009): 308–17. http://dx.doi.org/10.1111/j.1600-0609.1981.tb01408.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

BASHEVKIN, MICHAEL L. "The Activated Partial Thromboplastin Time." Annals of Internal Medicine 105, no. 3 (September 1, 1986): 470. http://dx.doi.org/10.7326/0003-4819-105-3-470_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

FRANCIS, ROBERT B. "The Activated Partial Thromboplastin Time." Annals of Internal Medicine 105, no. 4 (October 1, 1986): 626. http://dx.doi.org/10.7326/0003-4819-105-4-626_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Spinler, Sarah A. "Activated Partial Thromboplastin Time Evaluation." Pharmacotherapy 21, no. 3 (March 2001): 363–64. http://dx.doi.org/10.1592/phco.21.3.363.34203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ames, Paul R. J., Maria Graf, Jeremy Archer, Nicola Scarpato, and Luigi Iannaccone. "Prolonged Activated Partial Thromboplastin Time." Clinical and Applied Thrombosis/Hemostasis 21, no. 2 (July 2, 2014): 149–54. http://dx.doi.org/10.1177/1076029614541516.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Esmedere Eren, Sevim, Cigdem Karakukcu, Mehmet Z. Ciraci, Yasemin Ustundag, and Musa Karakukcu. "Activated partial thromboplastin time derivative curves." Blood Coagulation & Fibrinolysis 29, no. 4 (June 2018): 410–14. http://dx.doi.org/10.1097/mbc.0000000000000728.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Low, C. L., G. Eisele, and G. R. Bailie. "Correlation of whole blood activated partial thromboplastin time and plasma activated partial thromboplastin time in haemodialysis patients." Nephrology Dialysis Transplantation 11, no. 12 (December 1, 1996): 2523. http://dx.doi.org/10.1093/oxfordjournals.ndt.a027236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Smythe, Maureen A., John M. Koerber, Sandra N. Nowak, Joan C. Mattson, Robert L. Begle, Susan J. Westley, and Mamtha Balasubramaniam. "Correlation between Activated Clotting Time and Activated Partial Thromboplastin Times." Annals of Pharmacotherapy 36, no. 1 (January 2002): 7–11. http://dx.doi.org/10.1345/aph.1a141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kuss, Erich. "Use of the Activated Partial Thromboplastin Time." Annals of Internal Medicine 109, no. 4 (August 15, 1988): 347. http://dx.doi.org/10.7326/0003-4819-109-4-347_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pedersen, Joseph T., Matthew R. Pincus, and Judith A. Rapiejko. "Comparison of Activated Partial Thromboplastin Time Reagents." Laboratory Medicine 19, no. 7 (July 1, 1988): 421–24. http://dx.doi.org/10.1093/labmed/19.7.421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Delicata, M., and H. Hambley. "Abnormal activated partial thromboplastin time and malignancy." Scottish Medical Journal 56, no. 3 (August 2011): 1–2. http://dx.doi.org/10.1258/smj.2011.011124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Mungall, D. "Activated Partial Thromboplastin Time vs Heparin Concentration." Archives of Internal Medicine 158, no. 11 (June 8, 1998): 1273–75. http://dx.doi.org/10.1001/archinte.158.11.1273.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hall, La'Teese, Sarah J. Murrey, and Arthur S. Brecher. "Aromatic Amines Exert Contrasting Effects on the Anticoagulant Effect of Acetaldehyde upon APTT." Advances in Hematology 2014 (2014): 1–8. http://dx.doi.org/10.1155/2014/735751.

Full text

Abstract:

The pharmacological effects of amphetamine, procaine, procainamide, DOPA, isoproterenol, and atenolol upon activated partial thromboplastin time in the absence and presence of acetaldehyde have been investigated. In the absence of acetaldehyde, amphetamine and isoproterenol exhibit a procoagulant effect upon activated partial thromboplastin time, whereas atenolol and procaine display anticoagulant effects upon activated partial thromboplastin time. DOPA and procainamide do not alter activated partial thromboplastin time. Premixtures of procaine with acetaldehyde produce an additive anticoagulant effect on activated partial thromboplastin time, suggesting independent action of these compounds upon clotting factors. Premixtures of amphetamine with acetaldehyde, as well as atenolol with acetaldehyde, generate a detoxication of the anticoagulant effect of acetaldehyde upon activated partial thromboplastin time. A similar statistically significant decrease in activated partial thromboplastin time is seen when procainamide is premixed with acetaldehyde for 20 minutes at room temperature. Premixtures of DOPA and isoproterenol with acetaldehyde do not affect an alteration in activated partial thromboplastin time relative to acetaldehyde alone. Hence, a selective interaction of atenolol, procaine, and amphetamine with acetaldehyde to produce detoxication of the acetaldehyde is suggested, undoubtedly due to the presence of amino, hydroxyl, or amide groups in these drugs.

APA, Harvard, Vancouver, ISO, and other styles

14

Tarasova, L. N., E. Yu Savinykh, G. K. Platonov, L. L. N. Tonin, and O. I. Rechkin. "Time test." Kazan medical journal 79, no. 3 (May 15, 1998): 227–31. http://dx.doi.org/10.17816/kazmj64179.

Full text

Abstract:

The data on standardization of the activated partial thromboplastin time test all over the world and in Russia are given. The method is used as a screening one and it is of importance for revealing disorders in the first coagulation phase (hemophilia diagnosis) and heparinotherapy control. Two lyophilized forms of partial thromboplastin made of cadaverine raw materials are developed. Their specificity in revealing hemophilia, therapy control by heparin fit for a year is confirmed. The diagnosticum of one of them is a basis of the kit for determining the activated partial thromboplastin time. The possibility of its use not only in performing the test by test tube methods but as well by semiautomatic and automatic machines.

APA, Harvard, Vancouver, ISO, and other styles

15

Favaloro, Emmanuel J. "Unfractionated heparin monitoring with activated partial thromboplastin time." Pathology 52 (February 2020): S36. http://dx.doi.org/10.1016/j.pathol.2020.01.138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lippi, Giuseppe, Gian Luca Salvagno, Luigi Ippolito, Massimo Franchini, and Emmanuel J. Favaloro. "Shortened activated partial thromboplastin time: causes and management." Blood Coagulation & Fibrinolysis 21, no. 5 (July 2010): 459–63. http://dx.doi.org/10.1097/mbc.0b013e328338dbe8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Douglas, Alexander D., Jo Jefferis, Rishi Sharma, Rachel Parker, Ashok Handa, and Jonathan Chantler. "Evaluation of Point-of-care Activated Partial Thromboplastin Time Testing by Comparison to Laboratory-based Assay for Control of Intravenous Heparin." Angiology 60, no. 3 (April 26, 2009): 358–61. http://dx.doi.org/10.1177/0003319709332958.

Full text

Abstract:

Introduction Patients on intravenous heparin require regular activated partial thromboplastin time monitoring. Laboratory-based activated partial thromboplastin time assays necessitate a delay between blood sampling and dose adjustment. Point-of-care testing could permit immediate dose adjustments, potentially enabling tighter control of anticoagulation. Aim To assess equivalence of activated partial thromboplastin time measured by conventional laboratory assay and by a novel proprietary point-of-care testing system (Hemochron Response, ITC, Thoratec Corporation, Edison, NJ) among surgical ward patients on intravenous heparin. Methods A total of 39 blood samples from patients on intravenous heparin were tested with both laboratory and point-of-care assays. Assay equivalence was assessed by Bland-Altman analysis. Results. Point-of-care measurements exceeded laboratory activated partial thromboplastin time by a mean of 15 seconds (standard deviation 19). In 19 cases (49%), the point-of-care measurement would have resulted in different heparin dosing from the laboratory activated partial thromboplastin time. Conclusions The Hemochron Response system is not sufficiently accurate for routine ward use compared with laboratory activated partial thromboplastin time assays.

APA, Harvard, Vancouver, ISO, and other styles

18

SELIGSOHN, URI. "The Activated Partial Thromboplastin Time and Factor Xl Deficiency." Annals of Internal Medicine 105, no. 5 (November 1, 1986): 805. http://dx.doi.org/10.7326/0003-4819-105-5-805_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Tsikouris, James P., Kenneth C. Jackson, Craig D. Cox, Gary E. Meyerrose, Jose A. Diaz, and Charles F. Seifert. "Thrombolytic fibrin specificity influences activated partial thromboplastin time prolongation." Journal of the American College of Cardiology 39 (March 2002): 331–32. http://dx.doi.org/10.1016/s0735-1097(02)81490-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hauser, Valerie M., and Susan L. Rozek. "Effect of Warfarin on the Activated Partial Thromboplastin Time." Drug Intelligence & Clinical Pharmacy 20, no. 12 (December 1986): 964–67. http://dx.doi.org/10.1177/106002808602001210.

Full text

Abstract:

Outpatients followed in an anticoagulation clinic were studied retrospectively to determine the effect of warfarin on the activated partial thromboplastin time (APTT). Twenty-nine patients were studied in part 1 of the trial to determine whether their APTT values were elevated when their prothrombin time (PT) was within 1.5 to 2.5 times the control PT. Part 2 was carried out using the data of 32 patients to determine whether a correlation existed between the degree of elevation of the patients' PT values due to warfarin and the concurrent degree of elevation of their APTT results. Baseline PT and APTT values and a minimum of three concurrent PT and APTT values determined during anticoagulation therapy with warfarin were used. Data were collected by chart review and review of Hematology Department records. Results indicated that a statistically significant difference was evident between the baseline APTT (30.79 sec) and the mean APTT (55.10 sec) when the PT was within the therapeutic range of 1.5 to 2.5 times the control while on warfarin therapy. Good linear correlation was evident (r = 0.821) between the degree of elevation of the PT and the degree of elevation of the APTT for the group. In most cases, a good linear correlation was also evident for individual patients. Routine ordering of concurrent APTT and PT tests for patients receiving warfarin therapy is not needed since the PT alone can be monitored under most circumstances.

APA, Harvard, Vancouver, ISO, and other styles

21

Nakav, Sigal, Dorit Blickstein, Pia Raanani, Esther Rabizadeh, and Galia Spectre. "Prolonged activated partial thromboplastin time with no clear explanation." Blood Coagulation & Fibrinolysis 31, no. 3 (April 2020): 225–28. http://dx.doi.org/10.1097/mbc.0000000000000894.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kim, Je Sang, Hyun Jong Lee, Ji Dong Sung, Hee-Jin Kim, Soo-Youn Lee, and June Soo Kim. "Monitoring of Unfractionated Heparin Using Activated Partial Thromboplastin Time." Clinical and Applied Thrombosis/Hemostasis 20, no. 7 (April 23, 2013): 723–28. http://dx.doi.org/10.1177/1076029613485153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Matsumoto, Takeshi, Hideo Wada, Naoki Fujimoto, Junki Toyoda, Yasunori Abe, Kohshi Ohishi, Yoshiki Yamashita, et al. "An Evaluation of the Activated Partial Thromboplastin Time Waveform." Clinical and Applied Thrombosis/Hemostasis 24, no. 5 (September 8, 2017): 764–70. http://dx.doi.org/10.1177/1076029617724230.

Full text

Abstract:

The activated partial thromboplastin time (APTT) waveform includes several parameters that are related to various underlying diseases. The APTT waveform was examined in various diseases. Regarding the pattern of APTT waveform, a biphasic pattern of the first or second derivative curve (DC) was observed in patients with hemophilia and patients positive for antiphospholipid (aPL) antibodies or coagulation factor VIII (FVIII) inhibitors. The time of the first and second DC and fibrin formation at 1/2 height were prolonged in patients with hemophilia, patients with inhibitors, patients positive for aPL, patients treated with anti-Xa agents, and patients with disseminated intravascular coagulation (DIC). These values all tended to decrease in pregnant women (at 28-36 weeks’ gestation). The height of the second derivative peak 1 was significantly lower in patients with hemophilia, patients with FVIII inhibitors, patients positive for aPL, patients treated with anti-Xa agents, and patients with DIC; these values tended to be significantly higher in pregnant women. The height of the first DC was significantly lower in patients who were positive for FVIII inhibitors and was significantly higher in patients treated with anti-Xa agents and pregnant women. The height of the first and second DC was useful for the analysis of hemophilia, FVIII inhibitor, and aPL.

APA, Harvard, Vancouver, ISO, and other styles

24

Park, Seok Gon, Seung Chul Kim, Min Joo Choi, Hyuk Soo Lee, Byoung Goo Min, Jongtae Cheong, and Kyoungkap Lee. "Heparin Monitoring in Sheep by Activated Partial Thromboplastin Time." Artificial Organs 27, no. 6 (June 2003): 576–80. http://dx.doi.org/10.1046/j.1525-1594.2003.07090.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Yuzaqi, Peppi Z., Eli Halimah, and Tatat Novianti. "Performance Evaluation of Four Activated Partial Thromboplastin Time Reagents." Pharmacology and Clinical Pharmacy Research 3, no. 2 (August 1, 2018): 33–40. http://dx.doi.org/10.15416/pcpr.v3i2.18103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Evans, G. O., and R. M. Flynn. "Activated partial thromboplastin time measurements in citrated canine plasma." Journal of Comparative Pathology 106, no. 1 (January 1992): 79–82. http://dx.doi.org/10.1016/0021-9975(92)90070-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Wiwanitkit, Viroj. "Activated Partial Thromboplastin Time Abnormality in Patients with Cholangiocarcinoma." Clinical and Applied Thrombosis/Hemostasis 10, no. 1 (January 2004): 69–71. http://dx.doi.org/10.1177/107602960401000112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Simko, Robert J., Faye FW Tsung, and Eric J. Stanek. "Activated Clotting Time Versus Activated Partial Thromboplastin Time for Therapeutic Monitoring of Heparin." Annals of Pharmacotherapy 29, no. 10 (October 1995): 1015–21. http://dx.doi.org/10.1177/106002809502901012.

Full text

Abstract:

Objective: To compare and contrast the activated partial thromboplastin time (aPTT) and the activated clotting time (ACT) for the therapeutic monitoring of heparin therapy. Data Sources: Relevant articles were identified through an English-language MEDLINE search from 1966 to 1995. Additional sources were identified from the reference lists of these articles. Study Selection: Studies that investigated the use and limitations of the individual assays and those offering direct comparisons were chosen for review. Data Extraction: Features demonstrating clinical applications and limitations of the aPTT and the ACT were extracted. Where possible, data suggesting preferential application of either assay also were extracted. Data Synthesis: Both the aPTT and ACT are clinically useful for the monitoring of heparin therapy. The aPTT is used more frequently for routine monitoring; the ACT is used in specialized situations requiring large heparin doses. The ACT is typically performed at bedside and is capable of yielding results rapidly and perhaps at a lower cost than an aPTT performed by a central laboratory. Most practitioners are familiar with the central laboratory aPTT. A bedside aPTT device is available, but is not yet in widespread clinical use. Both assay techniques are subject to various limitations. Conclusions: The ACT is theoretically equally as useful as the aPTT for the routine monitoring of heparin therapy, but has not been well-studied. The ACT appears more useful in situations in which high serum concentrations of heparin are required. Further cost-effectiveness and clinical outcome studies directly comparing the ACT and the aPTT in specific clinical situations are needed.

APA, Harvard, Vancouver, ISO, and other styles

29

Patel, Vasant B., and David J. Moliterno. "Bedside activated partial thromboplastin time monitoring: Just a matter of time?" American Heart Journal 137, no. 1 (January 1999): 8–11. http://dx.doi.org/10.1016/s0002-8703(99)70454-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Thomason, T., B. Riegel, D. Jessen, Smith SCJr, I. Gocka, and M. Rich. "Clinical safety and cost of heparin titration using bedside activated clotting time." American Journal of Critical Care 2, no. 1 (January 1, 1993): 81–87. http://dx.doi.org/10.4037/ajcc1993.2.1.81.

Full text

Abstract:

OBJECTIVE: To evaluate the clinical safety of heparin titration and the procedural cost of anticoagulation measurement using bedside low-range activated clotting time. DESIGN: Quasi-experimental study using data gathered through retrospective record review. SETTING: Coronary care, medical intensive care and telemetry units of a community hospital. SUBJECTS: Sample of 102 patients undergoing elective percutaneous transluminal coronary angioplasty. INTERVENTION: Intravenous heparin therapy was titrated using low-range activated clotting time in 51 percutaneous transluminal coronary angioplasty patients. Data from this group were compared to a matched sample of 51 angioplasty patients whose intravenous heparin therapy was titrated using activated partial thromboplastin time. RESULTS: No differences in procedural, early or late complications were found between the groups. The cost of managing heparin therapy with low-range activated clotting time was less than with activated partial thromboplastin time. CONCLUSION: These results suggest that titrating heparin therapy based on bedside low-range activated clotting time for the angioplasty patients in this sample was as safe as with activated partial thromboplastin time. Use of bedside low-range activated clotting time saved money for the hospital.

APA, Harvard, Vancouver, ISO, and other styles

31

Tse, Enrica, Rshmi Khurana, Gwen Clarke, and Winnie Sia. "Using anti-Xa level for adjusting intravenous unfractionated heparin infusion in peripartum thromboembolic disease." Obstetric Medicine 12, no. 3 (May 17, 2018): 146–50. http://dx.doi.org/10.1177/1753495x18772993.

Full text

Abstract:

Background Intravenous unfractionated heparin infusion is often used to minimize the duration of time without anticoagulation around delivery in pregnant patients with high thrombotic risk. Activated partial thromboplastin time is commonly used to monitor and adjust heparin dose. However, using activated partial thromboplastin time is problematic in pregnancy because activated partial thromboplastin time response to unfractionated heparin is attenuated due to elevated Factor VIII levels and may lead to incorrect dosing. Case We report a case of deep venous thrombosis occurring in a term pregnancy managed by intravenous unfractionated heparin adjusted using anti-Xa level around the time of delivery. We modified the intravenous unfractionated heparin nomogram by using anti-Xa levels instead of activated partial thromboplastin time and observed lower dosing of unfractionated heparin than otherwise required to achieve and maintain target levels. Conclusion This report demonstrates the feasibility and effectiveness of using anti-Xa level to monitor and adjust intravenous unfractionated heparin infusion in pregnancy.

APA, Harvard, Vancouver, ISO, and other styles

32

Laxson, CJ, and MG Titler. "Drawing coagulation studies from arterial lines: an integrative literature review." American Journal of Critical Care 3, no. 1 (January 1, 1994): 16–22. http://dx.doi.org/10.4037/ajcc1994.3.1.16.

Full text

Abstract:

How much blood must be discarded from a heparinized arterial line to obtain accurate coagulation studies, specifically activated partial thromboplastin time? The published literature provides insight into the question and guidelines for practice in adult critical care. This article reviews and integrates findings from 14 research studies published from 1971 to 1993 on discarding blood from arterial lines for coagulation studies. Investigators compared activated partial thromboplastin time values from arterial and venous blood samples using various discard volumes, sites and sizes of catheters, and heparin flush concentrations. Similarities and differences in arterial and venous activated partial thromboplastin time were reported. Studies have demonstrated that adequate discard volume for activated partial thromboplastin time is 6 times the catheter dead space. These results should not be generalized to systemically heparinized patients, pediatric patients, or other types of heparinized lines such as pulmonary artery, central venous, or Hickman catheters.

APA, Harvard, Vancouver, ISO, and other styles

33

Lippi, Giuseppe, Martina Montagnana, Gian Luca Salvagno, and Gian Cesare Guidi. "Interference of Blood Cell Lysis on Routine Coagulation Testing." Archives of Pathology & Laboratory Medicine 130, no. 2 (February 1, 2006): 181–84. http://dx.doi.org/10.5858/2006-130-181-iobclo.

Full text

Abstract:

Abstract Context.—Preanalytical factors influencing the reliability of laboratory testing are commonplace. It is traditionally accepted that hemolytic samples are unsuitable for coagulation assays because of the release of hemoglobin, intracellular components, and thromboplastic substances from damaged blood cells. Objective.—To evaluate the influence of blood cell lysis on routine coagulation testing. Design.—Twelve aliquots prepared by serial dilutions of homologous lysated samples collected from 10 different subjects, and displaying a final percentage of lysis ranging from 0% to 9.1%, were tested for prothrombin time, activated partial thromboplastin time, fibrinogen, and dimerized plasmin fragment D. Lysis was achieved by subjecting citrated whole blood to a freeze-thaw cycle. Outcome Measures.—Interference from blood cell lysis on routine coagulation testing. Results.—Statistically significant increases in prothrombin time and dimerized plasmin fragment D were observed in samples containing final lysate concentrations of 0.5% and 2.7% respectively, whereas significant decreases were observed in activated partial thromboplastin time and fibrinogen in samples containing a final lysate concentration of 0.9%. The current analytical quality specifications for desirable bias are ±2.0% for prothrombin time, ±2.3% for activated partial thromboplastin time, and ±4.8% for fibrinogen. Percent variations from the baseline values exceeding the current analytical quality specifications for desirable bias were achieved for lysate concentrations of 0.9% (prothrombin time and activated partial thromboplastin time) and 1.8% (fibrinogen), corresponding to average free plasma hemoglobin concentrations of 1.7 and 3.4 g/L, respectively. Conclusion.—Our results confirm that, although slightly hemolyzed specimens might still be analyzable, a moderate blood cell lysis, as low as 0.9%, influences the reliability of routine coagulation testing. Because the interference in coagulation assays has a wide interindividual bias, we do not recommend lysis correction and we suggest that the most appropriate corrective measure should be free hemoglobin quantification and sample recollection.

APA, Harvard, Vancouver, ISO, and other styles

34

Koerber, John M., Maureen A. Smythe, Robert L. Begle, Joan C. Mattson, Beverly P. Kershaw, and Susan J. Westley. "Correlation of Activated Clotting Time and Activated Partial Thromboplastin Time to Plasma Heparin Concentration." Pharmacotherapy 19, no. 8 (August 1999): 922–31. http://dx.doi.org/10.1592/phco.19.11.922.31573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gannon, Michelle, and Pamela B. Simone. "Impact of a Nurse-Driven Heparin Monitoring Protocol for Ventricular Assist Devices." AACN Advanced Critical Care 32, no. 2 (June 15, 2021): 146–51. http://dx.doi.org/10.4037/aacnacc2021803.

Full text

Abstract:

Background: Ventricular assist devices require anticoagulation to reduce thrombosis risk. Nurse-driven unfractionated heparin monitoring protocols have been validated for various indications, although data in patients with ventricular assist devices are lacking. Objective: To evaluate a nurse-driven protocol for managing unfractionated heparin therapy in stable patients with ventricular assist devices. Methods: This was a retrospective analysis of adult patients with ventricular assist devices requiring unfractionated heparin therapy, divided into 2 groups: before and after protocol implementation. The primary outcome was time to first therapeutic activated partial thromboplastin time. Results: Each group included 29 patients. There was no difference between the preintervention and postintervention groups in time to therapeutic activated partial thromboplastin time (25 vs 23 hours, P = .95) or proportion of patients with therapeutic activated partial thromboplastin time within the first 24 hours (45% vs 34%, P = .42). Suspected pump thrombosis and bleeding events were similar in the 2 groups. Conclusion: A nurse-driven heparin monitoring protocol was similar in time to therapeutic activated partial thromboplastin time compared with provider-driven monitoring and adjustments in patients with ventricular assist devices.

APA, Harvard, Vancouver, ISO, and other styles

36

Patel, Hemaxi, Toral Jivani, and Purvi Patel. "Comparative Study of Prothrombin Time, Activated Partial Thromboplastin Time and Platelet Counts in Type II Diabetes Mellitus and Healthy Individual." Indian Journal of Pathology: Research and Practice 8, no. 5 (2019): 686–89. http://dx.doi.org/10.21088/ijprp.2278.148x.8519.26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Templin, K., M. Shively, and J. Riley. "Accuracy of drawing coagulation samples from heparinized arterial lines." American Journal of Critical Care 2, no. 1 (January 1, 1993): 88–95. http://dx.doi.org/10.4037/ajcc1993.2.1.88.

Full text

Abstract:

OBJECTIVE: To determine the accuracy of activated partial thromboplastin time and prothrombin time studies when samples are drawn through heparinized arterial lines. METHODS: A total sample of 90 grouped blood samples (from 30 subjects) was used. Patients were all male, with a mean age of 65 and were studied within 24 hours of percutaneous transluminal coronary angioplasty. Each patient had three venous control and arterial line sample sets (a total of 90 blood samples) drawn when routinely ordered for monitoring therapy. For the arterial line sample, a discard volume of the deadspace, deadspace + 2 mL, or deadspace + 4 mL was randomly assigned for each sample. The venous control volumes were the same for all three sample sets. RESULTS: A 2 x 3 repeated measures analysis of variance was used to analyze the results. The independent variables were the source of the sample (venous vs arterial) and the discard volume of arterial blood (deadspace, deadspace + 2 mL, deadspace + 4 mL). The dependent variables were the activated partial thromboplastin time and prothrombin time values. Mean arterial activated partial thromboplastin time values were significantly higher than the corresponding venous values. Mean activated partial thromboplastin time values were not significantly different among the discard volumes of blood drawn. However, there was a significant source by volume interaction. Tukey post-hoc comparisons of venous-arterial activated partial thromboplastin time differences among the three volumes showed significant differences between deadspace volume and deadspace + 2 mL, and deadspace volume and deadspace + 4 mL. There was no significant difference between deadspace + 2 mL and deadspace + 4 mL volumes. CONCLUSION: Results indicated that the minimal amount of discard volume for accurate activated partial thromboplastin time values in this population of percutaneous transluminal coronary angioplasty patients was the catheter deadspace volume plus 2 mL (total 3.6 mL).

APA, Harvard, Vancouver, ISO, and other styles

38

Fatima, Mahvesh, and Ch N. Rajkumari. "Influence of ABO Blood Groups on Activated Partial Thromboplastin Time." International Journal of Physiology 5, no. 1 (2017): 60. http://dx.doi.org/10.5958/2320-608x.2017.00013.0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Santos García, Alba, Isabel Millán del Valle, Leonidas Cruzado Vega, Rosalía Ruiz Ferrús, Diana Tordera Fuentes, Alejandra Sabater Belmar, Romina Valenciano Moreno, and Angela Mompel Sanjuan. "Prolonged activated partial thromboplastin time without coagulopathy in peritoneal dialysis." Nefrología (English Edition) 39, no. 2 (March 2019): 210–11. http://dx.doi.org/10.1016/j.nefroe.2019.03.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Smythe, Maureen A., John M. Koerber, Susan J. Westley, Sandra N. Nowak, Robert L. Begle, Mamtha Balasubramaniam, and Joan C. Mattson. "Use of the Activated Partial Thromboplastin Time for Heparin Monitoring." American Journal of Clinical Pathology 115, no. 1 (January 2001): 148–55. http://dx.doi.org/10.1309/n7ra-d6xn-9eqx-abj9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Zakai, N. A., T. Ohira, and R. White. "Activated Partial Thromboplastin Time and Risk of Future Venous Thromboembolism." Journal of Vascular Surgery 48, no. 4 (October 2008): 1062. http://dx.doi.org/10.1016/j.jvs.2008.08.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Refsum, Nina, D. Collen, H. C. Godal, T. Janson, P. M. Mannucci, Inga Marie Nilsson, and C. C. Gilhuus-Moe. "Sensitivity and Precision of Activated Partial Thromboplastin Time (APTT) Methods." Scandinavian Journal of Haematology 20, no. 1 (April 24, 2009): 89–95. http://dx.doi.org/10.1111/j.1600-0609.1978.tb01559.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Moneta, G. L. "Activated Partial Thromboplastin Time and Risk of Future Venous Thromboembolism." Yearbook of Vascular Surgery 2009 (January 2009): 273–75. http://dx.doi.org/10.1016/s0749-4041(09)79137-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Zhou, Kehua, Diana Mehedint, and Haider Khadim. "Prolonged activated partial thromboplastin time due to plasma prekallikrein deficiency." Blood Coagulation & Fibrinolysis 30, no. 6 (September 2019): 300–303. http://dx.doi.org/10.1097/mbc.0000000000000837.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Mina, Ashraf, Emmanuel J. Favaloro, Soma Mohammed, and Jerry Koutts. "A laboratory evaluation into the short activated partial thromboplastin time." Blood Coagulation & Fibrinolysis 21, no. 2 (March 2010): 152–57. http://dx.doi.org/10.1097/mbc.0b013e3283365770.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Nurmohamed, Michael T., René J. Berckmans, Willy M. Morriën-Salomons, Fenny Berends, Daan W. Hommes, Joep J. M. M. Rijnierse, and Augueste Sturk. "Monitoring Anticoagulant Therapy by Activated Partial Thromboplastin Time: Hirudin Assessment." Thrombosis and Haemostasis 72, no. 05 (1994): 685–92. http://dx.doi.org/10.1055/s-0038-1648943.

Full text

Abstract:

SummaryBackground. Recombinant hirudin (RH) is a new anticoagulant for prophylaxis and treatment of venous and arterial thrombosis. To which extent the activated partial thromboplastin time (APTT) is suitable for monitoring of RH has not been properly evaluated. Recently, a capillary whole blood device was developed for bed-side monitoring of the APTT and it was demonstrated that this device was suitable to monitor heparin therapy. However, monitoring of RH was not evaluated.Study Objectives. To evaluate in vitro and ex vivo the responsiveness and reproducibility for hirudin monitoring of the whole blood monitor and of plasma APTT assays, which were performed with several reagents and two conventional coagulometers.Results. Large interindividual differences in hirudin responsiveness were noted in both the in vitro and the ex vivo experiments. The relationship between the APTT, expressed as clotting time or ratio of initial and prolonged APTT, and the hirudin concentration was nonlinear. A 1.5-fold increase of the clotting times was obtained at 150-200 ng/ml plasma. However, only a 2-fold increase was obtained at hirudin levels varying from 300 ng to more than 750 ng RH/ml plasma regardless of the assays. The relationship linearized upon logarithmic conversion of the ratio and the hirudin concentration. Disregarding the interindividual differences, and presuming full linearity of the relationship, all combinations were equally responsive to hirudin.Conclusions. All assays were equally responsive to hirudin. Levels up to 300 ng/ml plasma can be reliably estimated with each assay. The manual device may be preferable in situations where rapid availability of test results is necessary.

APA, Harvard, Vancouver, ISO, and other styles

47

Lippi, Giuseppe, and Emmanuel Favaloro. "Activated Partial Thromboplastin Time: New Tricks for an Old Dogma." Seminars in Thrombosis and Hemostasis 34, no. 07 (October 2008): 604–11. http://dx.doi.org/10.1055/s-0028-1104539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Cannon, Christopher P., Jasper Dingemanse, Cornelis H. Kleinbloesem, Thomas Jannett, Kenneth M. Curry, and Christian P. Valcke. "Automated Heparin-Delivery System to Control Activated Partial Thromboplastin Time." Circulation 99, no. 6 (February 16, 1999): 751–56. http://dx.doi.org/10.1161/01.cir.99.6.751.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Russo, Linda A., Andrew Bernstein, Manish Sheth, Dilip V. Patel, Shahid Ahmed, Anita K. Siddiqui, and Archana Bhargava. "Prolonged Activated Partial Thromboplastin Time In Pregnancy: A Brief Report." American Journal of the Medical Sciences 327, no. 3 (March 2004): 123–26. http://dx.doi.org/10.1097/00000441-200403000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Yao, Ke, Lingyun Zhang, Hang Zhou, Ning Tang, and Dengju Li. "Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays." American Journal of the Medical Sciences 354, no. 1 (July 2017): 22–26. http://dx.doi.org/10.1016/j.amjms.2017.03.031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!